News, info and tips for living with multiple sclerosis

What’s New About COVID-19 Vaccines and MS?

What’s New About COVID-19 Vaccines and MS?

A little over a year ago, I wrote about whether people with multiple sclerosis (MS) should get a COVID-19 vaccine. I was anxious to be vaccinated as soon as I could, but I was also concerned about how the vaccines would affect someone with MS.

Would the side effects be worse for MS patients than for healthy people? Would the disease-modifying therapies (DMTs) used to treat MS affect the ability of the COVID-19 vaccines to do their job, or might the vaccines actually exacerbate our illness?

Fast-forward to today, and it looks as if we have the answers to those questions.

Similar vaccine reactions

My first question was answered by a survey of 719 vaccinated people with MS conducted by iConquerMS, a people-powered research organization, that was published in the journal Neurology. The survey reports that there’s not much difference between the side effects that people with MS experienced and those reported by healthy people.

A reaction after the first shot was reported by 64% of people with MS. The most common reactions were injection site pain (54%), fatigue (34%), headache (28%), and malaise (21%). In a smaller group of people with MS who received a second shot, 74% reported similar side effects.

Interestingly, as illustrated in the chart below, the percentage of MS patients reporting a reaction was somewhat lower than the percentage reported by healthy people during clinical trials. This was particularly true regarding injection pain. (Maybe MS patients are just more used to getting stuck with needles.)

COVID-19 vaccine | Multiple Sclerosis News Today | A chart shows the frequency of vaccination reactions among clinical trial participants and  those who took part in the COVER-MS project
Courtesy: iConquerMS

Efficacy depends on the DMT

The type of DMT an MS patient has been treated with can affect the ability of vaccines to protect against COVID-19. Most DMTs work by reducing the activity of the immune system, lessening the inflammation that drives MS. But doing this could also dampen the ability of the immune system to fight the SARS-CoV-2 virus that causes COVID-19.

The concern is primarily with anti-CD20 therapies — Kesimpta (ofatumumab), Ocrevus (ocrelizumab), rituximab, and Gilenya (fingolimod). A study published in the Annals of Neurology reports that after being vaccinated, patients treated with these DMTs were about 96% less likely to show an immune response to the virus than people not using an anti-CD20 DMT. But no significant effect on COVID-19 vaccine efficacy was detected in people treated with eight other DMTs, treatments that didn’t attack CD20 B-cells.

No evidence COVID-19 vaccines exacerbate MS

I have read anecdotal reports of people who have experienced MS flares after receiving a COVID-19 vaccine Many of these these seem to be pseudo-flares, related to the fever these shots may cause for a day or two. But, I’ve read some social media reports of more serious reactions.

The vaccines are “not likely to trigger an MS relapse or have any impact on long-term disease progression,” according to experts with the National Multiple Sclerosis Society.

Should you get vaccinated?

I hope there is no one still on the fence about whether to get a COVID-19 vaccine. The timing of it may require a discussion with a neurologist, especially for patients being treated with an anti-CD20 therapy. (The National MS Society has an excellent list of timing considerations on its website.) But bottom line, the society believes the risks of contracting COVID-19 outweigh any potential risks from the COVID-19 vaccines, and it recommends that people with MS should be vaccinated.

I’ve had my two Moderna shots, plus the booster, and the vaccine didn’t impact my MS at all. And, believe me, when someone we’d been in close contact with recently became ill with COVID-19, I was very glad to have the jabs.

(A version of this post first appeared as my column on the MS News Today website.)

(Featured image by Wilfried Pohnke from Pixabay.)